Lipid emulsion treatment for local anesthetic systemic toxicity in pediatric patients: A systematic review
Soo Hee Lee,Sunmin Kim,Ju-Tae Sohn
DOI: https://doi.org/10.1097/md.0000000000037534
IF: 1.6
2024-03-17
Medicine
Abstract:Local anesthetics are widely used for peripheral nerve block, local infiltration, and spinal and epidural anesthesia. While the occurrence of local anesthetic systemic toxicity (LAST) is rare, it is fatal. Lipid emulsion, originally developed for parenteral nutrition in 1961, is now widely used to treat LAST. [ 1 ] In addition, lipid emulsion was reported to be effective in treating intractable systemic toxicity in pediatric patients caused by non-local anesthetic drugs with a high lipid solubility, which is unresponsive to supportive treatments. [ 2 ] The incidence of LAST in children was estimated to be 8 per 100,000 nerve blocks (95% confidence interval: 0.3–1.6). LAST is induced mainly by inadvertent intravascular injection or overdose of local anesthetic; it causes cardiac arrhythmia, myocardial depression, and cardiac arrest via inhibition of cardiac sodium, potassium, and calcium channels. [ 3 ] In addition, LAST causes central nervous systemic symptoms such as seizures. [ 3 ] Predominantly, regional anesthesia in children is administered while they are under general anesthesia, and diagnosis of LAST may be delayed, increasing the risk of LAST. [ 4 , 5 ] When comparing pharmacokinetics with adults, the pediatric population generally exhibits decreased drug absorption, protein binding of the drug, metabolism, and excretion, whereas volume of distribution of the drug is increased. [ 6 ] Amino-amide local anesthetics are metabolized by the hepatic cytochrome P450 enzymes and extensively bind to α1-acid glycoprotein. [ 7 ] Neonates and infants have low levels of α1-acid glycoproteins and the immature form of hepatic microsomal enzymes, leading to increased free form of amino-amide local anesthetics and decreased metabolism, respectively. [ 5 ] Thus, the risk of LAST in neonates and infants may be increased. [ 5 ] Moreover, pediatric patients who were born prematurely, have low muscle mass, and suffer from hepatic or cardiac diseases, may have an increased risk of LAST compared with the healthy pediatric population. Presently, no systematic reviews have been conducted on lipid emulsion treatment for LAST in pediatric patients. Thus, the goal of this study was to analyze and review case reports, retrieved through PubMed and Scopus databases, on lipid emulsion treatment for LAST in pediatric patients (<19 years old).
medicine, general & internal